ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
NLS Pharma Announces Phase 2 Study of NLS-1 has Met All Primary, Secondary Endpoints
May 17, 2017NLS Pharma Group announced its "Double-Blind Placebo-Controlled Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention Deficit Hyperactivity D
Pharma Sources Insight January 2025
